MONTREAL, Jan. 13, 2020 /CNW/ – Mondias Natural Products
Inc. (TSXV: NHP) (the "Company" or
"Mondias") specializing in evidence-based botanical products
for the healthcare and bio-agriculture markets, today announces
that it is extending the close of its non-brokered financing of
unsecured convertible debentures in the principal amount of
CAD$500,000, as previously disclosed
on a November 28, 2019, news release,
to January 15, 2020. All of the
previously disclosed terms of the financing remain unchanged.
The Company will use the proceeds to implement a digital
marketing campaign, launch new natural health products, further
pursue strategic partnerships and for general corporate
purposes. The Offering of the Debentures is subject to the
receipt of all necessary approvals, including the final approval of
the TSX Venture Exchange.
About Mondias Natural Products Inc.
Mondias
specializes in the commercialization and development of
evidence-based botanical products for the healthcare,
bio-agriculture and organic markets. The company sells both oral
and topical botanical agents to help manage unmet medical needs
through its Holizen Laboratories division. Mondias is also
developing botanical-based specialty fertilizers for use on
household plants, lawns and golf courses and in urban gardens,
nurseries and greenhouses, in collaboration with McGill's Faculty
of Agricultural and Environmental Sciences.
For more information, visit: www.mondias.ca
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-looking statements
Some statements in this
release may contain forward-looking information. All statements,
other than statements of historical fact, that address activities,
events or developments that the Company believes, expects or
anticipates will or may occur in the future (including, without
limitation, statements regarding potential acquisitions and
financings) are forward-looking statements. Forward-looking
statements are generally identifiable by the use of the words
"may", "will", "should", "continue", "expect", "anticipate",
"estimate", "believe", "intend", "plan" or "project" or the
negative of these words or other variations on these words or
comparable terminology. Forward-looking statements are subject to a
number of risks and uncertainties, many of which are beyond the
Company's ability to control or predict, that may cause the actual
results of the Company to differ materially from those discussed in
the forward-looking statements. Factors that could cause actual
results or events to differ materially from current expectations
include the Company's inability to obtain sufficient financing to
execute its business plan; competition; regulation; anticipated and
unanticipated costs and delays; the success of the Company's
research and development strategies; the ability to obtain orphan
drug status; the applicability of the discoveries made; the
successful and timely completion and uncertainties related to the
regulatory approval process; the timing of clinical trials; the
timing and outcomes of regulatory or intellectual property
decisions; and other risks disclosed in the Company's public
disclosure record on file with the relevant securities regulatory
authorities. Although the Company has attempted to identify
important factors that could cause actual results or events to
differ materially from those described in forward-looking
statements, there may be other factors that cause results or events
not to be as anticipated, estimated or intended. Readers should not
place undue reliance on forward-looking statements. The
forward-looking statements in this news release are made as of the
date of this news release, and the Company does not undertake any
obligation to publicly update them to reflect new information or
subsequent events or otherwise except as required by applicable
securities legislation.
SOURCE Mondias Natural Products Inc.